$MODD

Werewolf Therapeutics (HOWL) rose 90% in after-hours trading, with key clinical trials ongoing. GeoVax (GOVX) gained 12.66%, preparing for a pivotal Phase 3 study. Greenwich LifeSciences (GLSI) increased 6.27%, extending share lock-up. Modular Medical (MODD) up 7.87%, planning Pivot pump rollout. Ovid Therapeutics (OVID) rose 6.93%, with multiple clinical milestones. BioVie (BIVI) up 4.84%, awaiting long COVID data.

Modular Medical (NASDAQ:MODD) said it is running a strategic pilot with IMO Health to build an EHR-based, terminology-powered algorithm that identifies diabetes patients likely to benefit from its Pivot insulin pump. The pilot will use clinician-guided phenotypes and IMO Health terminology value sets, supporting a planned Pivot commercial launch in Q4 2026.

Modular Medical, Inc. (Nasdaq: MODD) announced that its CEO, Jeb Besser, will present at Tribe Public's webinar "From FDA Wins to Scaling Manufacturing - What Investors Should Watch" on Friday, May 1, 2026. The event will focus on Modular Medical's newly FDA-cleared Pivot insulin patch pump, designed to make insulin delivery more accessible and affordable for the 4.8 million Americans with diabetes. Investors are encouraged to register to learn about the company's commercial and manufacturing timelines, as well as its strategy to target the large underserved market of individuals currently using multiple daily injections.

Modular Medical (NASDAQ: MODD) announced a free webinar titled "From FDA Wins to Scaling Manufacturing - What Investors Should Watch" featuring CEO Jeb Besser on May 1, 2026. The webinar will discuss the company's Pivot tubeless insulin patch pump, which received FDA 510(k) clearance, and its commercialization and manufacturing timelines. This event comes as only 20% of the 4.8 million insulin-dependent diabetics in the U.S. currently use an insulin pump, highlighting a significant market opportunity for Modular Medical's innovative device.

Modular Medical, Inc. (NASDAQ:MODD) announced the pricing of a registered direct offering of 750,000 shares of its common stock at $4.50 per share, aiming to raise approximately $3.4 million in gross proceeds. The offering is expected to close around April 21, 2026, with Maxim Group LLC acting as the sole placement agent. The company specializes in patient-centric insulin delivery technology and seeks to make high-quality glycemic control more accessible and affordable.

Modular Medical, Inc. director and ten percent owner C. Frank Morgan received fully vested stock options to purchase an additional 312 shares of common stock as compensation. The options were granted under the company’s Outside Director Compensation Plan with an exercise price of $4.55 per share and are immediately exercisable, reflecting a neutral filing impact and sentiment. This Form 4 filing details two separate grants for 62 and 250 shares, both expiring on March 31, 2036.

Modular Medical, Inc. director Philip Brent Sheibley was granted 250 fully vested stock options with an exercise price of $4.55 per share, under the company's Outside Director Compensation Plan. The options are exercisable immediately and expire on March 31, 2036. This transaction was reported in a Form 4 SEC filing by StockTitan.

Modular Medical (NASDAQ: MODD) director Jeff D. Goldberg was granted 250 stock options on March 31, 2026. The options have an exercise price of $4.55 per share, were fully vested on the grant date, and expire on March 31, 2036. This grant was part of the company’s Outside Director Compensation Plan.

Shares of Modular Medical, Inc. (NASDAQ:MODD) increased by 2.6% on Wednesday, with the stock closing at $0.2203 despite declining trading volume. This movement is important to investors who are monitoring the company's progress in developing and commercializing its insulin pump products. The stock's rise occurred even as one analyst maintained a 'sell' rating on the shares, following a recent quarterly loss per share of $0.11.

Modular Medical Inc. (NASDAQ:MODD) has been granted a 180-day extension by Nasdaq to meet the minimum bid price requirement of $1.00 per share, giving the company until June 29, 2026. Currently trading at $0.36, MODD faces significant challenges, as failure to comply could lead to delisting. The company, focused on insulin delivery technology, recently announced a $4.68 million public offering and is progressing with its Pivot tubeless insulin patch pump, pending FDA clearance.